CN105998280A - Anti-haze medical and edible dual-purpose cordyceps militaris and snow lotus herb composition and preparation method and application thereof - Google Patents
Anti-haze medical and edible dual-purpose cordyceps militaris and snow lotus herb composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN105998280A CN105998280A CN201610288489.6A CN201610288489A CN105998280A CN 105998280 A CN105998280 A CN 105998280A CN 201610288489 A CN201610288489 A CN 201610288489A CN 105998280 A CN105998280 A CN 105998280A
- Authority
- CN
- China
- Prior art keywords
- parts
- haze
- fresh
- compositions
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 241001264174 Cordyceps militaris Species 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 240000002853 Nelumbo nucifera Species 0.000 title abstract description 5
- 235000006508 Nelumbo nucifera Nutrition 0.000 title abstract description 5
- 235000006510 Nelumbo pentapetala Nutrition 0.000 title abstract description 5
- 235000009008 Eriobotrya japonica Nutrition 0.000 claims abstract description 20
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 20
- 206010000496 acne Diseases 0.000 claims abstract description 15
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 10
- 206010008570 Chloasma Diseases 0.000 claims abstract description 8
- 208000003351 Melanosis Diseases 0.000 claims abstract description 8
- 235000013361 beverage Nutrition 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000008187 granular material Substances 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 6
- 239000003826 tablet Substances 0.000 claims abstract description 6
- 239000000706 filtrate Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 241001145025 Saussurea involucrata Species 0.000 claims description 20
- 241000218236 Cannabis Species 0.000 claims description 19
- 241000190633 Cordyceps Species 0.000 claims description 19
- 241001092070 Eriobotrya Species 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 17
- 239000002994 raw material Substances 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 6
- 230000006870 function Effects 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 abstract description 5
- 208000020816 lung neoplasm Diseases 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 3
- 244000276331 Citrus maxima Species 0.000 abstract 1
- 235000001759 Citrus maxima Nutrition 0.000 abstract 1
- 244000061508 Eriobotrya japonica Species 0.000 abstract 1
- 235000006751 Platycodon Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 240000004308 marijuana Species 0.000 abstract 1
- 229930189914 platycodon Natural products 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000003595 mist Substances 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 206010039101 Rhinorrhoea Diseases 0.000 description 4
- 208000010753 nasal discharge Diseases 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 4
- 206010040882 skin lesion Diseases 0.000 description 4
- 231100000444 skin lesion Toxicity 0.000 description 4
- 206010011732 Cyst Diseases 0.000 description 3
- 206010028748 Nasal obstruction Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000013618 particulate matter Substances 0.000 description 3
- 208000037921 secondary disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000222065 Lycoperdon Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000804765 Mus musculus Lymphotactin Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241000768494 Polymorphum Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010040952 Skin warm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003526 lymphopoietic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an anti-haze medical and edible dual-purpose cordyceps militaris and snow lotus herb composition and a preparation method and application thereof. The composition is prepared from 10-55 parts of cordyceps militaris, 10-40 parts of fresh loquat fruit pulp, 13-37 parts of fructus cannabis, 6-18 parts of platycodon roots, 5-33 parts of fresh dandelions, 4-13 parts of pummelo peel and 0.05-8 parts of snow lotus herb culturing substances. Fresh ingredients and dry ingredients are separated, mixing extracting, concentrating and drying are conducted, acceptable auxiliary materials are added, and then all the materials can be prepared into beverages, tablets, capsules, granules and oral solutions which can prevent and treat haze damage and can be used for preparing compositions for removing acne and chloasma and treating a lung cancer.
Description
Technical field
The present invention relates to medicine, field of health care food, be specifically related to a kind of anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions and its system
Preparation Method, relates to a kind of anti-haze medicine-food two-purpose Cordyceps anti-haze of Herba Saussureae Involueratae compositions and dispels acne, functions of removing chloasma, treatment pulmonary carcinoma in preparation
Compositions in application.
Background technology
Haze, also referred to as gray haze (smog), the particle such as dust in air, sulphuric acid, nitric acid, organic hydrocarbon compounds also can make greatly
Gas is muddy.The horizontal visibility of object is referred to as mist or mist in this phenomenon of 1000～ten thousand metres.Air when forming mist
Humidity should be saturated (in the presence of a large amount of nuclei of condensation, relative humidity not necessarily reaches 100% it is possible to occur saturated).By
The light of the mist scattering formed in aqueous water or ice crystal is little with wavelength relationship, thus mist seems to be creamy white or Bluish white and Lycoperdon polymorphum Vitt.
Along with Development of Urbanization and the acceleration of process of industrialization, industrial waste gas, vehicle exhaust, building building cement dirt, coal smoke dirt, rubbish
The unordered discharge of the pollutant such as rubbish burning, causes the pollutant such as the dust in air, antibacterial, virus and pellet serious
Exceeding standard, they combine with fog, allow sky moment become the most gloomy, formation haze weather, the most in recent years,
Along with air quality runs down, haze weather phenomenon occur frequency more and more higher, under this weather, when people trip or
During routine work life, molecule in air (refer mainly to the diameter particulate matter less than or equal to 2.5 microns, i.e. PM2.5,
Also referred to as can enter lung particulate matter) will be directly entered and stick in human respiratory tract and alveolar.Especially submicron particle can divide
It is not deposited in upper and lower respiratory tract and alveolar, causes the disease such as acute rhinitis and acute bronchitis.For bronchial asthma,
The chronic respiratory system diseases patients such as chronic bronchitis, obstructive emphysema and chronic obstructive pulmonary disease, haze weather can make
State of an illness acute attack or acute exacerbation.If being chronically at this environment also can induce pulmonary carcinoma.
The radical cure of haze requires time for, at present when by the efficacy of a drug, moistening the lung and resolving phlegm, to help the self-cleaning ability of lung, makes harmful particulate matter
Discharge with expectorant.Medicine-food two-purpose composition not only has that drug resistance is low, side effect and the advantage such as untoward reaction is few, is suitable for long-term taking,
But also there is many comprehensive effects, it sucks infringing party mask at preventing and treating haze advantage and the vast potential for future development of uniqueness.
Summary of the invention
Present invention seek to address that the problems referred to above, the first purpose is to provide one that multiple medicine-food two-purpose composition is carried out reasonable formula,
Can substantially effectively play and utilize effect of raw material ingredient, integrate the anti-haze medicine-food two-purpose worm for the treatment of and health care
Grass Herba Saussureae Involueratae compositions, the second purpose is to provide the preparation method of a kind of anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions, the 3rd purpose
It is to provide a kind of anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions in the compositions preparing dispel acne, functions of removing chloasma, treatment pulmonary carcinoma
Application.
For achieving the above object, the present invention provides a kind of anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions, said composition contain following
The raw material of weight portion: Cordyceps militaris (L.) Link. 10～55 parts, fresh loquat fruit 10～40 parts, Fructus Cannabis 13～37 parts, Radix Platycodonis 6～18 parts,
Fresh Herba Taraxaci 5～33 parts, Exocarpium Citri Grandis 4～13 parts, Saussurea involucrata culture 0.05～8 parts.
Preferably, the present invention provides a kind of anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions, said composition contain following weight portion
Raw material: Cordyceps militaris (L.) Link. 14～52 parts, fresh loquat fruit 14～33 parts, Fructus Cannabis 17～31 parts, Radix Platycodonis 8～15 parts, fresh Pu is public
English 11～25 parts, Exocarpium Citri Grandis 6～9 parts, Saussurea involucrata culture 0.1～5 parts.
A kind of anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions of the present invention, can add acceptable adjuvant, make tablet, capsule,
Granule, oral liquid, beverage.
The present invention provides the preparation method of a kind of anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions, carries out as follows: (1) is by joining
Side weighs the fresh loquat fruit of weight portion, Fructus Cannabis, fresh Herba Taraxaci, smashed 60～150 mesh sieves, and added 2～5 times of water, stir
Mix 30～90 minutes, filter, collect filtrate, standby；
(2) filtering residue in above-mentioned (1) is added Cordyceps militaris (L.) Link., Radix Platycodonis, Exocarpium Citri Grandis, add 6～15 times of water, decoct extraction 2 times, often
Secondary 1～3 hour, filter, collect filtrate, merge filtrate in above-mentioned (1) and (2), concentrating under reduced pressure, dry, pulverize into
80～120 mesh powder, standby；
(3) powder in above-mentioned (2) is added Saussurea involucrata culture and proper auxiliary materials, make tablet, capsule, granule, oral liquid,
Beverage.
On the other hand, it is an object of the invention to provide a kind of anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions, in preparation, there is acne of dispelling
Application in the compositions of effect.
Furthermore, it is an object of the invention to provide a kind of anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions, in preparation, there is functions of removing chloasma work
Compositions in application.
Make it is further an object that provide a kind of anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions to have treatment pulmonary carcinoma in preparation
Compositions in application.
Detailed description of the invention
The present invention is further illustrated, the raw material used by following embodiment, test example, reagent material below by detailed description of the invention
Material etc., if no special instructions, all buy commercially available prod, raw material such as: Cordyceps militaris (L.) Link., Fructus Cannabis, Radix Platycodonis, Exocarpium Citri Grandis are from medical material
Market；Fresh loquat fruit be the clean sarcocarp after fresh Folium Eriobotryae enucleation, fresh Herba Taraxaci be the fresh aerial parts of Herba Taraxaci, be all from
Market is criticized in agriculture；Saussurea involucrata culture is from Puri health bio tech ltd, Dalian.Following example are merely to illustrate the present invention,
Wherein said experimental technique, as without specifically defined, being conventional method.
Embodiment 1
Raw material: Cordyceps militaris (L.) Link. 10 parts, fresh loquat fruit 10 parts, Fructus Cannabis 13 parts, Radix Platycodonis 6 parts, fresh Herba Taraxaci 33 parts, Exocarpium Citri Grandis
4 parts, Saussurea involucrata culture 8 parts.
Preparation method: (1) weighs the fresh loquat fruit 10 parts of weight portion, Fructus Cannabis 13 parts, fresh Herba Taraxaci 33 parts, smashes 150
Mesh sieve, adds 5 times of water, stirs 90 minutes, filters, and collects filtrate, standby；
(2) filtering residue in above-mentioned (1) is added Cordyceps militaris (L.) Link. 10 parts, Radix Platycodonis 6 parts, Exocarpium Citri Grandis 4 parts, add 6 times of water, decoct and extract
2 times, each 1 hour, filter, collect filtrate, merge filtrate in above-mentioned (1) and (2), concentrating under reduced pressure, be dried, powder
It is broken into 100 mesh powder, standby；
(3) powder in above-mentioned (2) is added Saussurea involucrata culture 8 parts and polyvinylpolypyrrolidone 1 part, silicified microcrystalline cellulose 0.8 part,
Magnesium stearate 0.01 part, makes tablet.
Embodiment 2
Raw material: Cordyceps militaris (L.) Link. 31 parts, fresh loquat fruit 26 parts, Fructus Cannabis 24 parts, Radix Platycodonis 12 parts, fresh Herba Taraxaci 5 parts, Exocarpium Citri Grandis
9 parts, Saussurea involucrata culture 0.05 part.
Preparation method: (1) weighs the fresh loquat fruit 26 parts of weight portion, Fructus Cannabis 24 parts, fresh Herba Taraxaci 5 parts, smashes 60
Mesh sieve, adds 2 times of water, stirs 30 minutes, filters, and collects filtrate, standby；
(2) filtering residue in above-mentioned (1) being added Cordyceps militaris (L.) Link. 31 parts, Radix Platycodonis 12 parts, Exocarpium Citri Grandis 9 parts, add 10 times of water, decoction carries
Take 2 times, each 2 hours, filter, collect filtrate, merge filtrate in above-mentioned (1) and (2), concentrating under reduced pressure, be dried,
It is ground into 80 mesh powder, standby；
(3) powder in above-mentioned (2) is added Saussurea involucrata culture 0.05 part and silicon dioxide 0.08 part, make capsule.
Embodiment 3
Raw material: Cordyceps militaris (L.) Link. 55 parts, fresh loquat fruit 40 parts, Fructus Cannabis 37 parts, Radix Platycodonis 18 parts, fresh Herba Taraxaci 19 parts, Exocarpium Citri Grandis
13 parts, Saussurea involucrata culture 3.9 parts.
Preparation method: (1) weighs the fresh loquat fruit 40 parts of weight portion, Fructus Cannabis 37 parts, fresh Herba Taraxaci 19 parts, smashes 100
Mesh sieve, adds 3.5 times of water, stirs 60 minutes, filters, and collects filtrate, standby；
(2) filtering residue in above-mentioned (1) is added Cordyceps militaris (L.) Link. 55 parts, Radix Platycodonis 18 parts, Exocarpium Citri Grandis 13 parts, add 15 times of water, decoct
Extract 2 times, each 3 hours, filter, collect filtrate, merge filtrate in above-mentioned (1) and (2), concentrating under reduced pressure, be dried,
It is ground into 120 mesh powder, standby；
(3) powder in above-mentioned (2) is added Saussurea involucrata culture 3.9 parts and mannitol 50 parts, sucralose 0.001 part, 70%
Ethanol 15 parts, makes granule.
Embodiment 4
Raw material: Cordyceps militaris (L.) Link. 52 parts, fresh loquat fruit 14 parts, Fructus Cannabis 31 parts, Radix Platycodonis 15 parts, fresh Herba Taraxaci 25 parts, Exocarpium Citri Grandis
9 parts, Saussurea involucrata culture 2.6 parts.
Preparation method: (1) weighs the fresh loquat fruit 14 parts of weight portion, Fructus Cannabis 31 parts, fresh Herba Taraxaci 25 parts, smashes 120
Mesh sieve, adds 4 times of water, stirs 70 minutes, filters, and collects filtrate, standby；
(2) filtering residue in above-mentioned (1) being added Cordyceps militaris (L.) Link. 52 parts, Radix Platycodonis 15 parts, Exocarpium Citri Grandis 9 parts, add 8 times of water, decoction carries
Take 2 times, each 2.5 hours, filter, collect filtrate, merge filtrate in above-mentioned (1) and (2), concentrating under reduced pressure, be dried,
It is ground into 100 mesh powder, standby；
(3) powder in above-mentioned (2) is added Saussurea involucrata culture 2.6 parts and erythritol 80 parts, fructose 5 parts, make solid
Beverage.
Embodiment 5
Raw material: Cordyceps militaris (L.) Link. 14 parts, fresh loquat fruit 33 parts, Fructus Cannabis 17 parts, Radix Platycodonis 8 parts, fresh Herba Taraxaci 11 parts, Exocarpium Citri Grandis
6 parts, Saussurea involucrata culture 0.1 part.
Preparation method: (1) weighs the fresh loquat fruit 33 parts of weight portion, Fructus Cannabis 17 parts, fresh Herba Taraxaci 11 parts, smashes 70
Mesh sieve, adds 3 times of water, stirs 50 minutes, filters, and collects filtrate, standby；
(2) filtering residue in above-mentioned (1) being added Cordyceps militaris (L.) Link. 14 parts, Radix Platycodonis 8 parts, Exocarpium Citri Grandis 6 parts, add 11 times of water, decoction carries
Take 2 times, each 1.5 hours, filter, collect filtrate, merge filtrate in above-mentioned (1) and (2), concentrating under reduced pressure, be dried,
It is ground into 120 mesh powder, standby；
(3) powder in above-mentioned (2) is added Saussurea involucrata culture 0.1 part and Mel 5 parts, oligofructose 2 parts, really glucose 25 parts,
Purified water 95 parts, makes oral liquid.
Embodiment 6
Raw material: Cordyceps militaris (L.) Link. 28 parts, fresh loquat fruit 22 parts, Fructus Cannabis 23 parts, Radix Platycodonis 11 parts, fresh Herba Taraxaci 18 parts, Exocarpium Citri Grandis
7.5 parts, Saussurea involucrata culture 5 parts.
Preparation method: (1) weighs the fresh loquat fruit 22 parts of weight portion, Fructus Cannabis 23 parts, fresh Herba Taraxaci 18 parts, smashes 80
Mesh sieve, adds 4.5 times of water, stirs 85 minutes, filters, and collects filtrate, standby；
(2) filtering residue in above-mentioned (1) is added Cordyceps militaris (L.) Link. 28 parts, Radix Platycodonis 11 parts, Exocarpium Citri Grandis 7.5 parts, add 13 times of water, decoct
Extract 2 times, each 1 hour, filter, collect filtrate, merge filtrate in above-mentioned (1) and (2), concentrating under reduced pressure, be dried,
It is ground into 80 mesh powder, standby；
(3) powder in above-mentioned (2) is added Saussurea involucrata culture 5 parts and Momordia grosvenori aglycone 0.001 part, fructose 10 parts, L-I
0.1 part of primary glue, purified water 1000 parts, make liquid beverage.
Test example
Test example 1, antiinflammatory action
Taking SD rat 50, male and female do not limit, and are randomly divided into 5 groups, often group 10, i.e. model group, Cefixime granule pair
According to group, the embodiment of the present invention 6 high, medium and low dosage group.Ig is administered, and every day 1 time, continuous 28 days, the 14th day, ig gave
Prepare model while medicine, i.e. under shallow fiber crops, in the dorsal sc injection 30ml air of every Mus to form air bag, then to
Inject genuine turpentine oil 1ml in air bag, after 20h, extract air in capsule out.After last is administered, 2h puts to death rat, and peels off meat in wall
Bud swells, and after normal saline rinses, claims dry weight after putting 60 DEG C of oven cooking cycle 48h.Result shows, the present invention can substantially suppress
The rat air bag granuloma hypertrophy of Oleum Terebinthinae induction, antiphlogistic effects is obvious.
The table 1 impact (x ± s) on Oleum Terebinthinae induced rat air bag granulation hyperplasia model
Compare with model group*P < 0.01,*P<0.05
Test example 2, impact on chloasma model mice
Take female KM mice, be randomly divided into 7 groups, often group 10 respectively: normal, model control group, glutathion compare
Group, Saussurea involucrata culture matched group, the embodiment of the present invention 4 high, medium and low dosage group.Normal group presses body weight intramuscular injection sterilization drug
Use level vegetable oil；Remaining 5 groups with Progesterone intramuscular injection, dosage is 30mg/kg.Every morning once, two lower limb alternate injection,
Continuous 28 days.Animal every morning ultraviolet irradiates 3 hours simultaneously.Modeling starts to gavage corresponding medicine every afternoon simultaneously,
Continuous 30 days.After last is administered, the skin that ultraviolet of learning from else's experience irradiates measures its liver lipofuscin.Result shows, the present invention is favourable
In reducing liver lipofuscin, eliminating chloasma.
The table 2 impact (x ± s) on chloasma model mice
Compare with model group*P < 0.05,*P<0.01
Test example 3, the lymphopoiesis of lotus Lewis lung cancer rat is affected
Take SD rat, male and female half and half, the Lewis lung cancer suspension 0.30ml/ Mus (about 2 × l0 of the aseptic preparation of abdominal cavity subcutaneous injection6
Individual tumor cell).Next day random packet, often group gavages corresponding medicine, and blank group gives corresponding distilled water, and last is administered
Within latter 48 hours, aseptically take Rats Spleen, make single splenocyte suspension with 150 eye mesh screens, with containing 20% inactivation calf
Serum free culture system liquid regulation cell concentration is l × l07Individual cell/ml, adds 96 porocyte culture plates, every hole 200ul (1 × 106Individual carefully
Born of the same parents/hole), add the culture fluid 100ul containing ConA (8ug, ml), put 37 DEG C, 10%CO2CMC model 72h.Inhale gently
Take supernatant l00ul, add MTT solution (6mg/m1) 20ul.Place 37 DEG C, 10%CO2Add after CMC model 24h and disappear
Change liquid 150ul, then place to survey each hole OD value next day and calculate stimulation index with formula.Stimulation index=experimental group OD value/right
According to group OD value.The division growth ability of lymphocyte reflects the power of Immune Function, lymph to a certain extent
Cell transformation test is the test method that testing machine body immunity function is conventional.Result shows that the present composition can be obviously promoted greatly
Mouse lymphotactin is bred and promotes Lewis lung cancer apoptosis.
The table 3 lymphopoietic impact (x ± s) on lotus Lewis lung cancer rat
Compare with blank group※※P<0.01
Test example 4, to treatment acne clinical observation
1, crowd and inclusive criteria
Collection volunteer, 18 years old age～32 years old, includes totally 47 people in, is randomly divided into treatment group 27 example and matched group 20 example.
There is following symptom: take place mostly in face and thoracic dorsal etc., show as blackhead, inflamed papules, secondary pustule or tuberosity,
Cyst etc..Tcm diagnosis: 1. wind-heat syndrome primary symptom: acne (blackhead, hoary hair) are in the majority, with red pimple.Secondary disease: face
Flushing, skin warms or scorching hot, breath gas heat, pain of itching.Tongue tip side of red, yellow and thin fur, rapid pulse.2. damp-heat syndrome primary symptom: skin
Greasy, based on painful pimple, pustule.Secondary disease a: nodosity, or with halitosis.Constipation, yellowish urine, red tongue, tongue
Yellow greasy, slippery and rapid pulse.3. heat toxin and blood stasis primary symptom: skin lesion is tuberosity and cyst, color is dark, and recurrent exerbation easily forms cicatrix.
Secondary disease: tuberosity and cyst matter are harder, dark tongue quality has petechia or ecchymosis, hesitant pulse.
2, Therapeutic Method
Matched group: FUFANG ZHENZHU ANCHUANG PIAN (0.33g/ sheet), 1 time 4,3 times on the 1st, take 28 days.
Treatment group: present composition embodiment 2, oral, three times a day, each consumption is equivalent to raw material 15g, takes 28 days.
3, criterion of therapeutical effect: effectively: acne count reduces > 30%, skin lesion degree alleviates；Invalid: acne count minimizing < 30%, skin lesion
Degree is unchanged.
4, therapeutic effect: the present composition has good therapeutic effect to acne.Concrete two groups of therapeutic effect are shown in Table 4, table 5.
The change (x ± s) of acne total quantity before and after the group treatment of 4 liang of table
The change (x ± s) of skin lesion degree integration before and after the group treatment of 5 liang of table
Test example 5, the clinical observation that treatment haze is damaged
1, crowd and inclusive criteria
Collection volunteer, 24 years old age～58 years old, includes totally 37 people in, is randomly divided into treatment group 19 example and matched group 18 example.
Western medicine diagnose: 1. have haze weather to go out operation history；With cough, expectoration, watery nasal discharge, shed tears, have a stuffy nose, sneeze, dry pharynx etc.
Disease；2. pharyngeal congestion or redness, tonsil inflammation, enlargement, two pulmonary respiration sounds are the most coarse or the most coarse, accompany or without dry and wet
Rale；3. peripheral blood conventional white cell calculates and is sorted between normal range or numeration of leukocyte is higher；4.X line chest film inspection
Normal.
2, Therapeutic Method
Matched group: Cefdinir dispersible tablet (50mg/ sheet), 1 time 2,3 times on the 1st, take 10 days.
Treatment group: present composition embodiment 3, oral, three times a day, each consumption is equivalent to raw material total amount 15g, takes 10
My god.
3, criterion of therapeutical effect: recovery from illness: the Clinical symptom and sign such as cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx disappearance in treat five days；
Effective: in treating five days, the Clinical symptom and sign such as cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx alleviates more than 2/3；
Effective: in treating five days, the Clinical symptom and sign such as cough, expectoration, watery nasal discharge, nasal obstruction, sneeze, dry pharynx alleviates 2/3～1/3；
Invalid: in treating five days, conscious or other symptoms are all not improved or increase the weight of.
4, therapeutic effect: the human body infringement that haze is caused by the present composition has good therapeutic effect.Concrete two groups of therapeutic effect are shown in
Table 6.
The result (x ± s) of 6 liang of table group therapeutic effect
The foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, all spirit in the present invention and former
Any amendment, equivalent and the improvement etc. made within then, should be included within the scope of the present invention.
Claims (7)
1. an anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions, it is characterised in that be made up of the raw material of following weight portion: Cordyceps militaris (L.) Link. 10～55
Part, fresh loquat fruit 10～40 parts, Fructus Cannabis 13～37 parts, Radix Platycodonis 6～18 parts, fresh Herba Taraxaci 5～33 parts, Exocarpium Citri Grandis
4～13 parts, Saussurea involucrata culture 0.05～8 parts.
A kind of anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions the most as claimed in claim 1, it is characterised in that by the raw material of following weight portion
Composition: Cordyceps militaris (L.) Link. 14～52 parts, fresh loquat fruit 14～33 parts, Fructus Cannabis 17～31 parts, Radix Platycodonis 8～15 parts, fresh Pu is public
English 11～25 parts, Exocarpium Citri Grandis 6～9 parts, Saussurea involucrata culture 0.1～5 parts.
3. the one anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions as described in claim 1 to 2 is arbitrary, it is characterised in that add acceptable
Adjuvant, make tablet, capsule, granule, oral liquid, beverage.
4. the preparation method of a kind of anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions as described in claims 1 to 3 is arbitrary, it is characterised in that
Comprise the steps:
(1) weigh the fresh loquat fruit of weight portion, Fructus Cannabis, fresh Herba Taraxaci by formula, smashed 60～150 mesh sieves, add 2～
5 times of water, stir 30～90 minutes, filter, and collect filtrate, standby；
(2) filtering residue in above-mentioned (1) is added Cordyceps militaris (L.) Link., Radix Platycodonis, Exocarpium Citri Grandis, add 6～15 times of water, decoct extraction 2 times, often
Secondary 1～3 hour, filter, collect filtrate, merge filtrate in above-mentioned (1) and (2), concentrating under reduced pressure, dry, pulverize into
80～120 mesh powder, standby；
(3) powder in above-mentioned (2) is added Saussurea involucrata culture and proper auxiliary materials, make tablet, capsule, granule, oral liquid,
Beverage.
5. the answering in the compositions preparing acne of dispelling of the anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions as described in Claims 1-4 is arbitrary
With.
6. the anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions as described in Claims 1-4 is arbitrary has the group of functions of removing chloasma effect in preparation
Application in compound.
7. the anti-haze medicine-food two-purpose Cordyceps Herba Saussureae Involueratae compositions as described in Claims 1-4 is arbitrary has the group for the treatment of pulmonary carcinoma effect in preparation
Application in compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610288489.6A CN105998280A (en) | 2016-04-28 | 2016-04-28 | Anti-haze medical and edible dual-purpose cordyceps militaris and snow lotus herb composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610288489.6A CN105998280A (en) | 2016-04-28 | 2016-04-28 | Anti-haze medical and edible dual-purpose cordyceps militaris and snow lotus herb composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105998280A true CN105998280A (en) | 2016-10-12 |
Family
ID=57081452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610288489.6A Pending CN105998280A (en) | 2016-04-28 | 2016-04-28 | Anti-haze medical and edible dual-purpose cordyceps militaris and snow lotus herb composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105998280A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107837355A (en) * | 2017-12-19 | 2018-03-27 | 北京昆达中医医学研究院 | A kind of medicine of the anti-haze of clearing lung-heat |
| CN108157972A (en) * | 2017-08-01 | 2018-06-15 | 楼良水 | With the cordyceps sinensis compound and solid beverage for improving immunity |
| CN108477457A (en) * | 2018-04-06 | 2018-09-04 | 张奉明 | A kind of dendrobium candidum composition and preparation method thereof of clear haze benefit lung |
| CN110693999A (en) * | 2019-10-10 | 2020-01-17 | 湖南炎帝生物工程有限公司 | Traditional Chinese medicine composition for treating lung injury, relieving cough, reducing phlegm and improving skin moisture, preparation and application |
| CN112998265A (en) * | 2021-05-13 | 2021-06-22 | 广东南粤药业有限公司 | Exocarpium citri grandis composition with cough relieving and phlegm reducing effects and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926842A (en) * | 2010-09-07 | 2010-12-29 | 郭景龙 | Medicinal composition prepared from raw materials containing snow lotus and fermented cordyceps fungal powder |
| CN103750339A (en) * | 2014-01-08 | 2014-04-30 | 大连普瑞康生物技术有限公司 | Saussurea involucrate culture health-care food and application thereof |
| CN104825970A (en) * | 2015-05-19 | 2015-08-12 | 贵州广济堂药业有限公司 | Health care product containing Noni juice |
| CN104839665A (en) * | 2015-04-10 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Chloasma conditioning medical formula food |
| CN104906358A (en) * | 2015-05-19 | 2015-09-16 | 贵州广济堂药业有限公司 | Health care product for nourishing yin, clearing away lung-heat and removing haze |
| CN105028836A (en) * | 2015-08-24 | 2015-11-11 | 青海高原红绿色保健制品有限公司 | Cordyceps militaris and Chinese wolfberry-containing tea capable of preventing haze and clearing away lung-heat and preparation method thereof |
-
2016
- 2016-04-28 CN CN201610288489.6A patent/CN105998280A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926842A (en) * | 2010-09-07 | 2010-12-29 | 郭景龙 | Medicinal composition prepared from raw materials containing snow lotus and fermented cordyceps fungal powder |
| CN103750339A (en) * | 2014-01-08 | 2014-04-30 | 大连普瑞康生物技术有限公司 | Saussurea involucrate culture health-care food and application thereof |
| CN104839665A (en) * | 2015-04-10 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Chloasma conditioning medical formula food |
| CN104825970A (en) * | 2015-05-19 | 2015-08-12 | 贵州广济堂药业有限公司 | Health care product containing Noni juice |
| CN104906358A (en) * | 2015-05-19 | 2015-09-16 | 贵州广济堂药业有限公司 | Health care product for nourishing yin, clearing away lung-heat and removing haze |
| CN105028836A (en) * | 2015-08-24 | 2015-11-11 | 青海高原红绿色保健制品有限公司 | Cordyceps militaris and Chinese wolfberry-containing tea capable of preventing haze and clearing away lung-heat and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 沈爱明等: "《中医护理学》", 30 June 2015, 东南大学出版社 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108157972A (en) * | 2017-08-01 | 2018-06-15 | 楼良水 | With the cordyceps sinensis compound and solid beverage for improving immunity |
| CN107837355A (en) * | 2017-12-19 | 2018-03-27 | 北京昆达中医医学研究院 | A kind of medicine of the anti-haze of clearing lung-heat |
| CN108477457A (en) * | 2018-04-06 | 2018-09-04 | 张奉明 | A kind of dendrobium candidum composition and preparation method thereof of clear haze benefit lung |
| CN110693999A (en) * | 2019-10-10 | 2020-01-17 | 湖南炎帝生物工程有限公司 | Traditional Chinese medicine composition for treating lung injury, relieving cough, reducing phlegm and improving skin moisture, preparation and application |
| CN112998265A (en) * | 2021-05-13 | 2021-06-22 | 广东南粤药业有限公司 | Exocarpium citri grandis composition with cough relieving and phlegm reducing effects and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105998280A (en) | Anti-haze medical and edible dual-purpose cordyceps militaris and snow lotus herb composition and preparation method and application thereof | |
| CN112274620A (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia, preparation method, detection method and application thereof | |
| CN102475835A (en) | Pharmaceutical composition for treating common cold or cough caused by common cold in children and preparation method thereof | |
| CN105326888A (en) | Medicinal composition for treating child phlegm-heat obstructing lung type asthma | |
| US9180153B2 (en) | Sophorae Radix extract for prevention and treatment of respiratory diseases | |
| CN105327104A (en) | Haze lung clearing drink | |
| CN112587602A (en) | Traditional Chinese medicine composition for relieving cough and reducing sputum, extract and preparation method and application thereof | |
| CN109239239B (en) | Traditional Chinese medicine composition for clearing lung, eliminating phlegm, relieving cough and asthma and preparation method and application thereof | |
| CN111643646A (en) | Traditional Chinese medicine preparation for preventing and treating new coronary pneumonia and preparation method and application thereof | |
| CN104840734B (en) | Clearing health-care Chinese medicinal composition and its preparation method and application | |
| CN106539908A (en) | A kind of Chinese medicine composition for treating allergic rhinitises and skin allergy | |
| CN103989762B (en) | Chinese medicine composition of internal organs relieving cough and resolving phlegm and preparation method thereof is rushed down in a kind of heat clearing away | |
| CN103751645B (en) | Pharmaceutical composition for the treatment of infant allergic rhinitis and preparation method thereof | |
| CN102949572A (en) | Medicinal composition for treating throat diseases, and its preparation method | |
| CN107714920B (en) | A kind of Chinese medicine composition and preparation method thereof with pharynx-clearing throat-benefiting antitussive action | |
| CN106075229A (en) | A kind of Chinese medicinal composition preparation treating anemopyretic cold | |
| CN105125837A (en) | Spray relieving asthma of bronchial asthma attack and preparation method thereof | |
| CN103784712A (en) | Health care product capable of repairing lung injuries caused by environmental pollution and preparation method of health care product | |
| CN108815376B (en) | Throat-clearing and sore-throat-relieving tea | |
| CN107041923A (en) | It is a kind of that there is clearing lung-heat, cough-relieving, composition of resolving sputum function and preparation method thereof | |
| CN104257956A (en) | Traditional Chinese medicine composition with effects of relieving cough and asthma | |
| CN104997916A (en) | Traditional Chinese medicine treating urethritis | |
| CN113855770A (en) | Traditional Chinese medicine composition for treating reflux esophagitis and preparation method thereof | |
| CN102764347A (en) | Medicament for treating cold and complications thereof | |
| CN108355048A (en) | A kind of aiding smoking cessation and treatment COPD in stable phase Chinese medicine compound prescription |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161012 |
|
| RJ01 | Rejection of invention patent application after publication |